February 17, 2017
1 min read
Save

Juvéderm Volbella XC effective for lip, perioral enhancements up to 1 year

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Juvéderm Volbella XC treatment for lip and perioral enhancement was safe and effective, with the effects of treatment lasting through 1 year, according to study results published in Dermatologic Surgery.

Roy G. Geronemus, MD, of the Laser & Skin Surgery Center of New York, and colleagues conducted a randomized study of 225 adults (median age, 54 years; 96.9% women) with minimal, mild or moderate lip fullness, using a validated 5-point Allergan Lip Fullness Scale (LFS). One hundred and sixty-nine patients were treated with Juvéderm Volbella XC (nonaminal crosslinked hyaluronic acid [HA] gel with lidocaine; Allergan; VYC-15), and 56 patients were treated with Restylane-L (nonaminal stabilized HA with lidocaine; NASHA; Medicis Aesthetics).

Roy G. Geronemus, MD
Roy G. Geronemus

Optional touch-up treatment was administered at 1 month, with follow-up for 1 year.

Noninferiority of VYC-15L versus NASHA by mean change in LFS score from baseline to month 3 was primary endpoint.

The LFS responder rates at month 3 were 80.3% for patients treated with VYC-15L compared with 70.8% for NASHA-treated patients. The patients treated with VYC-15L had LFS responder rates exceeding 60% through 1 year.

The patients treated with VYC-15L had perioral line severity improvement of 65.4% at 3 months and of 66.2% at 1 year. Improvement in FASE-Q Satisfaction with Lips and Satisfaction with Lip Lines were reported by 96.1% and 88.2% patients in the VYC-15L cohort, respectively.

Common injection site responses included swelling, firmness, and lumps and bumps, with rates being 5 percentage points or more for patients treated with VYC-15L compared with NASHA for redness, pain after injection, itching and discoloration. The VYC-15L cohort had less frequently reported severe ISRs (46.1%) compared with the NASHA group (56%).

“These findings illustrate the effectiveness of VYC-15L for lip and perioral enhancement.,” the researchers wrote. “This study shows that YVC-15L is safe and effective for lip and perioral enhancement, with treatment effects persisting through 1 year.”  by Bruce Thiel

Disclosure: The study was supported by Allergan. Geronemus reports being an investigator for Allergan. Please see the full study for a list of other researchers’ relevant financial disclosures.